Edwards Lifesciences Co. (NYSE:EW) Receives $90.67 Average PT from Analysts

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seventeen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $90.67.

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a research report on Thursday, March 21st. Stifel Nicolaus raised their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a "hold" rating in a research note on Wednesday, February 7th. Oppenheimer raised their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, March 18th. Wells Fargo & Company raised shares of Edwards Lifesciences from an "equal weight" rating to an "overweight" rating and set a $94.00 price objective for the company in a research note on Friday, February 2nd. Finally, Citigroup raised their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 3rd.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Michael A. Mussallem sold 29,350 shares of the business's stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $92.42, for a total value of $2,712,527.00. Following the completion of the sale, the director now owns 4,486 shares of the company's stock, valued at approximately $414,596.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares of the company's stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 204,004 shares of company stock worth $17,922,954 in the last quarter. 1.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of EW. Nordea Investment Management AB grew its position in Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company's stock worth $123,261,000 after purchasing an additional 1,488,791 shares during the last quarter. Arlington Trust Co LLC grew its position in Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company's stock worth $938,000 after purchasing an additional 12,069 shares during the last quarter. Versor Investments LP grew its position in Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company's stock worth $311,000 after purchasing an additional 2,043 shares during the last quarter. Gateway Investment Advisers LLC grew its position in Edwards Lifesciences by 12.2% in the 4th quarter. Gateway Investment Advisers LLC now owns 253,337 shares of the medical research company's stock worth $19,317,000 after purchasing an additional 27,519 shares during the last quarter. Finally, US Bancorp DE grew its position in Edwards Lifesciences by 0.6% in the 3rd quarter. US Bancorp DE now owns 850,257 shares of the medical research company's stock worth $58,906,000 after purchasing an additional 5,409 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW traded up $0.71 during mid-day trading on Tuesday, hitting $93.05. 2,631,109 shares of the company's stock were exchanged, compared to its average volume of 3,969,763. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm has a market capitalization of $56.01 billion, a P/E ratio of 40.46, a P/E/G ratio of 4.59 and a beta of 1.05. The business's 50 day moving average is $89.41 and its two-hundred day moving average is $77.34. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts' consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm's revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.64 earnings per share. On average, equities analysts expect that Edwards Lifesciences will post 2.76 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.